Cannabis Science Inc (OTCMKTS:CBIS) shares have been listing to the downside in a corrective wave over the past 30-45 days, along with seemingly a majority of high flyers in the cannabis patch over that time. CBIS has continued to build out its operational potency, announcing this week that it received notice of coming delivery of its pre-designed greenhouses, with full tracking and reporting protocols to be delivered this week as they set up operations at sites in California and Nevada.
“Having control over our own supply chain will greatly increase our efficiencies, including the time and cost required to have processed product readily available for development into all our formulations. We will soon launch our observational studies for specific cannabinoid combinations targeting critical ailments. We will be growing a variety of cannabinoid combinations for our formulations and testing. Each formulation is designed to target a specific critical ailment; to work using a particular delivery mode; and to have the potency to drive maximum positive results in patient usage,” stated CMO Dr. Allen Herman.
Cannabis Science Inc (OTCMKTS:CBIS) has been down an interesting road over recent months. We see the company as actively striving for, and achieving a bump in legitimacy through some of its newly established relationships.
The company defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.
The company is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
Cannabis Science Inc also has collaboration with IGXBio, Inc. to develop GenePro, a DNA-based immunotherapeutic drug.
In addition, CBIS offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.
Find out when $CBIS stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to the company’s latest release, they have been inundated with emails inquiring about the timing of clinical research and the availability of treatment options.
“These inquiries cover the management of pain, peripheral neuropathies, cancer, and COPD. All inquiries are entered into our in-house database and we will be responding to each person as each targeted observational study officially commences. The studies will include some of the over 500 cannabinoids that have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis. Common plant cannabinoids (phytocannabinoids) include: tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). The pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis. Our in-house database will form the basis of patient-centered outcomes research (PCOR) for a variety of critical conditions.”
CBIS shares have slid about -8% over the past week of action. Moreover, the stock has seen trading interest climb during that decline, with an increase in recent trading volume of 24% above its longer-run average levels.
If we get picky with this stock here, we would point out what has become a difficult balance sheet situation. Cannabis Science is currently rolling along with virtually no cash on the books, weighed against over $2M in total current liabilities. And that debt pile has been growing over recent quarters. While there is some reported revenue flow over the past twelve months, the company has clearly operationally reinvented itself and is now back in a development phase, albeit with famously big plans.
While much of what’s happening here seems to carry potential for CBIS, we would urge investors to weight the company’s current framing in the context of its prior history of convertible debt dilution. As that balance sheet tips into the red zone, it’s important to see press out of the company clarifying the timeline for something that is tangible on the go-to-market front. For continuing coverage on shares of $CBIS stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!